Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease

NCT00702689 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Sclerotic Graft Versus Host Disease
Imatinib Mesylate

Interventions

DRUG: Gleevec, STI571(Imatinib Mesylate)

Sponsor

National Cancer Institute (NCI)